Sign in

or Register now

MyRACentral.com

See all of our health sites at www.HealthCentral.com
Sunday, November, 22, 2009
  • Font size
  • Bookmark
  • Save
Receive a FREE Osteoarthritis of the knee pamphlet.  Start here.

Christine Miller's SharePosts

Environmental and Geographic Influences on RA

Last week at the American College of Rheumatology annual meeting, researchers from the Mayo Clinic presented new data finding that from 1995-2005 the incidence and prevalence of rheumatoid arthritis rose in women after having declined from the mid-1950's through the mid 1990's.   Since 1995, the incidence has risen from 36 women out of... Read moreChevron

Think Positive is Theme of 2008 World Arthritis Day...And Words to Live By

            Sunday, October 12 was World Arthritis Day.  This year's theme, "Think Positive," aimed to help people recognize and discuss the physical and emotional challenges associated with all forms of arthritis as well as positive things one can do to help increase self-confidence and... Read moreChevron

FDA Delays Approval of Actemra

            The FDA has delayed approval for Actemra pending submission of extra product manufacturing and product label information by the drug manufacturer, Roche Holding AG.  This comes a week after requiring ordering label changes for Rituxan, which is manufactured by Genentech and... Read moreChevron

Another Warning Label Change: Rituxan Label Changed Again After RA Patient Contracts Brain Infection

On September 11, the FDA, Genentech and Biogen Idec (the manufacturers of Rituxan) announced that the labeling for the drug is being revised.  This comes after the first report that a patient taking Rituxan to treat rheumatoid arthritis had died of the brain infection progressive multifocal leukoencephalopathy (PML).  Rituxan is approved... Read moreChevron

New FDA Warnings for TNF Inhibitors- What are the Fungal Diseases Involved?

What are the warnings? The U.S. Food and Drug Administration just announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing “Black Box” warnings because of the risk of developing opportunistic fungal infections. These warnings are located in the Warnings and Precaution sections of the... Read moreChevron

  • Font size
  • Bookmark
  • Save
  • Report abuse

Ask a Question

Get answers from our experts and community members.

View all questions (1951) >